IP Library › Granted Patent US 10,829,535
Granted Patent B2
US 10,829,535 · App. 15/901,705 · Granted Nov 10, 2020

Interleukin-2 muteins for the expansion of T-regulatory cells

Inventors: Marc A. Gavin (Vashon, WA); Gunasekaran Kannan (Daly City, CA); Li Li (San Bruno, CA); Joshua T. Pearson (San Francisco, CA); Margaret Karow (Santa Rosa Valley, CA)
Assignee: Amgen Inc.
C07K14/55C07K16/00A61K38/00C07K2317/41C07K2317/52C07K2317/524C07K2317/71C07K2317/94C07K2319/21C07K2319/30C07K2319/43
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,829,535
App. No.
15/901,705
Granted
Nov 10, 2020
Kind
B2
Abstract

Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.

Claims (5)

1. A human interleukin-2 (IL-2) mutein comprising a V91K and T3N substitution and an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:1, wherein position 125 is an alanine and wherein said IL-2 mutein preferentially stimulates T regulatory cells.

2. A human interleukin-2 (IL-2) mutein comprising a V91K and S5T substitution and an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:1, wherein position 125 is an alanine and wherein said IL-2 mutein preferentially stimulates T regulatory cells.

3. The human IL-2 mutein of claim 2 , further comprising a T3N substitution.

4. A human interleukin-2 (IL-2) mutein comprising a V91K substitution and an amino acid sequence having 95% identity to the amino acid sequence as set forth in SEQ ID NO:1, wherein position 125 is an alanine and wherein said IL-2 mutein preferentially stimulates T regulatory cells.

5. The human IL-2 mutein of claim 4 , wherein the human IL-2 mutein has 100% identity to the amino acid sequence as set forth in SEQ ID NO:1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2018
From: GAVIN, MARC A.; KANNAN, GUNASEKARAN; LI, LI; PEARSON, JOSHUA T.; KAROW, MARGARET
To: AMGEN INC.
Reel/Frame 045758/0945 →
Continuity (4)
Division 15408281 · Jan 17, 2017
Division 14209699 · Mar 13, 2014
Provisional Application 61784669 · Mar 14, 2013
Related Publication 20180319859A1 · Nov 8, 2018
Cited By (3)
US 12,297,249 US 12,303,567 US 12,642,840